Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
IPO Year:
Exchange: NASDAQ
Website: https://www.embecta.com
Recent Analyst Ratings for Embecta Corp.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $15.00 | Neutral | Mizuho |
| 12/2/2024 | $13.00 → $20.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/27/2024 | $26.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | Peer Perform | Wolfe Research | |
| 1/6/2023 | $28.00 | Equal-Weight → Underweight | Morgan Stanley |
| 9/8/2022 | Neutral | BTIG Research | |
| 8/1/2022 | $33.00 | Equal-Weight | Morgan Stanley |
| 6/21/2022 | $25.00 | Underperform | BofA Securities |
Embecta Corp. Press Releases
Fastest customizable press release news feed in the world
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. The publication introduces the FITTER Forward Expert Recommendations, an updated set of global best practices for insulin injection technique and education. Authored by a panel of 16 diabetes specialists from 13 countries, the FITTER Forward initiative highlights the critical need for improved training and standardization in insulin delivery, aiming to enhance clinical outcomes for millions of people with diabetes worldwide. "When physicians and nur
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference
PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET. About embectaembecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram. Contacts: Media
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. "Building on our momentum from 2024, embecta began the year with solid performance," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "We remain on track to complete the restructuring plan associated with the discontinuation of the insulin patch pump program by the end of the first half of the fiscal year and are preparing to launch our brand transition plan in the second half, beginning in the U.S. and Canada. Additionally, we continue to make progr
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channe
embecta to Report Fiscal First Quarter 2025 Financial Results
PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on February 6, 2025, via the embec
embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Audio webcasts of the presentations will be accessible under the "News & Events" section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishments include the successful transition of approximately 98% of our revenue to our own ERP system, shared service capabilities, and distribution infrastructure, with India remaining as o
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
Embecta Corp. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Mizuho initiated coverage on Embecta Corp. with a new price target
Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00
Embecta Corp. upgraded by Morgan Stanley with a new price target
Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously
Embecta Corp. upgraded by BTIG Research with a new price target
BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00
Wolfe Research initiated coverage on Embecta Corp.
Wolfe Research initiated coverage of Embecta Corp. with a rating of Peer Perform
Embecta Corp. downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded Embecta Corp. from Equal-Weight to Underweight and set a new price target of $28.00
BTIG Research initiated coverage on Embecta Corp.
BTIG Research initiated coverage of Embecta Corp. with a rating of Neutral
Morgan Stanley initiated coverage on Embecta Corp. with a new price target
Morgan Stanley initiated coverage of Embecta Corp. with a rating of Equal-Weight and set a new price target of $33.00
BofA Securities initiated coverage on Embecta Corp. with a new price target
BofA Securities initiated coverage of Embecta Corp. with a rating of Underperform and set a new price target of $25.00
Embecta Corp. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Embecta Corp. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z covered exercise/tax liability with 5,285 shares, decreasing direct ownership by 4% to 139,439 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
President and CEO Kurdikar Devdatt covered exercise/tax liability with 39,592 shares, decreasing direct ownership by 7% to 499,582 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Director Morris Milton Mayo was granted 13,839 shares and sold $50,783 worth of shares (3,100 units at $16.38), increasing direct ownership by 42% to 36,133 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Director Albritton David was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Director Anderson Carrie L was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Director Prange Karen was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Director Reidy Christopher R was granted 13,839 shares, increasing direct ownership by 44% to 45,284 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
Embecta Corp. SEC Filings
Embecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - Embecta Corp. (0001872789) (Filer)
SEC Form 144 filed by Embecta Corp.
144 - Embecta Corp. (0001872789) (Subject)
SEC Form 10-Q filed by Embecta Corp.
10-Q - Embecta Corp. (0001872789) (Filer)
Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Embecta Corp. (0001872789) (Filer)
SEC Form DEFA14A filed by Embecta Corp.
DEFA14A - Embecta Corp. (0001872789) (Filer)
SEC Form DEF 14A filed by Embecta Corp.
DEF 14A - Embecta Corp. (0001872789) (Filer)
SEC Form 10-K filed by Embecta Corp.
10-K - Embecta Corp. (0001872789) (Filer)
Embecta Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Embecta Corp. (0001872789) (Filer)
SEC Form NT 10-K filed by Embecta Corp.
NT 10-K - Embecta Corp. (0001872789) (Filer)
Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits
8-K - Embecta Corp. (0001872789) (Filer)
Embecta Corp. Leadership Updates
Live Leadership Updates
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
Revelyst Announces Chief Supply Chain Officer
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell
PARSIPPANY, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell today, in recognition of National Diabetes Awareness Month in November. The coming year is also a time to celebrate the company's heritage in providing solutions to people living with diabetes, including 100 years since the development and launch of the first syringe dedicated to insulin delivery. Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diabetes Education and Camping Association (DECA),
Campbell Appoints Carrie Anderson Chief Financial Officer
Campbell Soup Company (NYSE:CPB) today announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective Feb. 6. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005725/en/Carrie Anderson (Photo: Business Wire) Anderson will lead Campbell's finance function, including controllership, corporate financial planning and analysis, corporate strategy and development, tax, treasury, internal audit, investor relations, transactional services and financial systems. She will report to Campbell's President and Chief Executive Officer Mark Clouse and become a member of the company's Operat
Nordson Corporation Appoints Milton Morris to Board of Directors
Nordson Corporation (NASDAQ:NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors. Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board. "We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson's strength of understanding customer needs and bringing diversified precision technology solutions to market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further exp
Embecta Corp. Financials
Live finance-specific insights
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. "Building on our momentum from 2024, embecta began the year with solid performance," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "We remain on track to complete the restructuring plan associated with the discontinuation of the insulin patch pump program by the end of the first half of the fiscal year and are preparing to launch our brand transition plan in the second half, beginning in the U.S. and Canada. Additionally, we continue to make progr
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channe
embecta to Report Fiscal First Quarter 2025 Financial Results
PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on February 6, 2025, via the embec
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishments include the successful transition of approximately 98% of our revenue to our own ERP system, shared service capabilities, and distribution infrastructure, with India remaining as o
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET
embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET
Embecta Corp. Reports Third Quarter Fiscal 2024 Financial Results
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024. "During the third quarter our business performed in alignment with our expectations. We generated strong gross, operating and EBITDA margins even as revenue was impacted by the expected timing of customer orders that had positively impacted our second quarter results," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "From a year-to-date perspective, our financial results demonstrated the contin
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
embecta to Report Fiscal Third Quarter 2024 Financial Results
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, Aug 9, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 9, 2024, via the embecta investor rela
Embecta Corp. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Embecta Corp.
SC 13G/A - Embecta Corp. (0001872789) (Subject)
Amendment: SEC Form SC 13G/A filed by Embecta Corp.
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G filed by Embecta Corp.
SC 13G - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G/A filed by Embecta Corp. (Amendment)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G/A filed by Embecta Corp. (Amendment)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G filed by Embecta Corp.
SC 13G - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G/A filed by Embecta Corp. (Amendment)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G filed by Embecta Corp.
SC 13G - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G/A filed by Embecta Corp. (Amendment)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SEC Form SC 13G/A filed by Embecta Corp. (Amendment)
SC 13G/A - Embecta Corp. (0001872789) (Subject)